Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 184

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 184
---
2 |
| Effective tax rate based on consolidated net income (IFRS) | 16.3% | 19.2% |
| Tax effects:                                               |       |       |
| Amortization and impairment of intangible assets           |  -0.3 |  -0.4 |
| Restructuring costs and similar items                      |   1.6 |  -0.3 |
| Other tax effects                                          |   0.1 |   1.2 |
| Effective tax rate based on business net income (non-IFRS) | 17.7% | 19.7% |

15/ Share of profit/(loss) from investments accounted for using the equity method The line item Share of profit/(loss) from investments accounted for using the equity method was a net loss of € 136 million in 2023 (including an impairment loss of €231 million on the equity-accounted investment in EUROAPI – see Note D.6.), compared with net income of € 55 million for 2022 16/ Net income from continuing operations Net income from continuing operations amounted to €5,098 million in 2023 , compared with €8,083 million in 2022 .

| 86 | SANOFIFORM 20-F2024 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

17/ Net income from discontinued operations In accordance with IFRS 5, the net income or loss of the Opella business is presented in a separate line item, “ Net income from discontinued operations ” (see Notes D.1. and D.36. to our consolidated financial statements). This business reported a net income of € 338 million in 2023, compared with net income of € 401 million in 2022. In 2023, this line item includes income tax expense of €365 million arising from taxable temporary differences relating to holdings in subsidiaries, because it became probable that those differences would reverse. 18/ Net income attributable to non-controlling interests Net income attributable to non-controlling interests was €36 million in 2023 , versus € 113 million in 2022 . 19/ Net income attributable to equity holders of Sanofi Net income attributable to equity holders of Sanofi amounted to €5,400 million in 2023 , compared with €8,371 million in 2022 . Basic earnings per share for 2023 was € 4.31 versus € 6.69 for